136 related articles for article (PubMed ID: 33289381)
21. SERS-Based Pump-Free Microfluidic Chip for Highly Sensitive Immunoassay of Prostate-Specific Antigen Biomarkers.
Gao R; Lv Z; Mao Y; Yu L; Bi X; Xu S; Cui J; Wu Y
ACS Sens; 2019 Apr; 4(4):938-943. PubMed ID: 30864786
[TBL] [Abstract][Full Text] [Related]
22. Automated 3D-Printed Microfluidic Array for Rapid Nanomaterial-Enhanced Detection of Multiple Proteins.
Kadimisetty K; Malla S; Bhalerao KS; Mosa IM; Bhakta S; Lee NH; Rusling JF
Anal Chem; 2018 Jun; 90(12):7569-7577. PubMed ID: 29779368
[TBL] [Abstract][Full Text] [Related]
23. [Statistical study of probabilities of rectal palpation, total PSA, and PSA density in prostate cancer].
Ortiz Cabria R; Adriazola Semino M; Tejeda Bañez E; Alonso Villalba A; García Cobo E; Romero Rodríguez F; Monfá Bosch JM
Arch Esp Urol; 2002; 55(1):35-40. PubMed ID: 11957749
[TBL] [Abstract][Full Text] [Related]
24. Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer.
Stephan C; Jung K; Semjonow A; Schulze-Forster K; Cammann H; Hu X; Meyer HA; Bögemann M; Miller K; Friedersdorff F
Clin Chem; 2013 Jan; 59(1):280-8. PubMed ID: 23213079
[TBL] [Abstract][Full Text] [Related]
25. Effects of increasing the PSA cutoff to perform additional biomarker tests before prostate biopsy.
Nordström T; Adolfsson J; Grönberg H; Eklund M
BMC Urol; 2017 Oct; 17(1):92. PubMed ID: 28974201
[TBL] [Abstract][Full Text] [Related]
26. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).
Roobol MJ; Kranse R; de Koning HJ; Schröder FH
Urology; 2004 Feb; 63(2):309-13; discussion 313-5. PubMed ID: 14972478
[TBL] [Abstract][Full Text] [Related]
27. Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer.
Lehrer S; Diamond EJ; Stagger S; Stone NN; Stock RG
Br J Cancer; 2002 Sep; 87(7):726-8. PubMed ID: 12232754
[TBL] [Abstract][Full Text] [Related]
28. Investigation on core-fucosylated prostate-specific antigen as a refined biomarker for differentiation of benign prostate hyperplasia and prostate cancer of different aggressiveness.
Lang R; Rolny V; Leinenbach A; Karl J; Swiatek-de Lange M; Kobold U; Schrader M; Krause H; Mueller M; Vogeser M
Tumour Biol; 2019 Mar; 41(3):1010428319827223. PubMed ID: 30907281
[TBL] [Abstract][Full Text] [Related]
29. A case control study of sarcosine as an early prostate cancer detection biomarker.
Ankerst DP; Liss M; Zapata D; Hoefler J; Thompson IM; Leach RJ
BMC Urol; 2015 Oct; 15():99. PubMed ID: 26429735
[TBL] [Abstract][Full Text] [Related]
30. Twenty-year Risk of Prostate Cancer Death by Midlife Prostate-specific Antigen and a Panel of Four Kallikrein Markers in a Large Population-based Cohort of Healthy Men.
Sjoberg DD; Vickers AJ; Assel M; Dahlin A; Poon BY; Ulmert D; Lilja H
Eur Urol; 2018 Jun; 73(6):941-948. PubMed ID: 29519548
[TBL] [Abstract][Full Text] [Related]
31. Prostate cancer detection at low prostate specific antigen.
Schröder FH; van der Cruijsen-Koeter I; de Koning HJ; Vis AN; Hoedemaeker RF; Kranse R
J Urol; 2000 Mar; 163(3):806-12. PubMed ID: 10687982
[TBL] [Abstract][Full Text] [Related]
32. Increased serum insulin associated with increased risk of prostate cancer recurrence.
Lehrer S; Diamond EJ; Stagger S; Stone NN; Stock RG
Prostate; 2002 Jan; 50(1):1-3. PubMed ID: 11757030
[TBL] [Abstract][Full Text] [Related]
33. Serum insulin-like growth factor-1 is not a useful marker of prostate cancer.
Cutting CW; Hunt C; Nisbet JA; Bland JM; Dalgleish AG; Kirby RS
BJU Int; 1999 Jun; 83(9):996-9. PubMed ID: 10368242
[TBL] [Abstract][Full Text] [Related]
34. Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions.
Hendriks RJ; van Oort IM; Schalken JA
Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):12-19. PubMed ID: 27922627
[TBL] [Abstract][Full Text] [Related]
35. Identification of a Candidate Gene Panel for the Early Diagnosis of Prostate Cancer.
Leyten GH; Hessels D; Smit FP; Jannink SA; de Jong H; Melchers WJ; Cornel EB; de Reijke TM; Vergunst H; Kil P; Knipscheer BC; Hulsbergen-van de Kaa CA; Mulders PF; van Oort IM; Schalken JA
Clin Cancer Res; 2015 Jul; 21(13):3061-70. PubMed ID: 25788493
[TBL] [Abstract][Full Text] [Related]
36. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests.
Mäkinen T; Tammela TL; Hakama M; Stenman UH; Rannikko S; Aro J; Juusela H; Määttänen L; Auvinen A
J Urol; 2001 Oct; 166(4):1339-42. PubMed ID: 11547069
[TBL] [Abstract][Full Text] [Related]
37. Development and validation of a 25-Gene Panel urine test for prostate cancer diagnosis and potential treatment follow-up.
Johnson H; Guo J; Zhang X; Zhang H; Simoulis A; Wu AHB; Xia T; Li F; Tan W; Johnson A; Dizeyi N; Abrahamsson PA; Kenner L; Feng X; Zou C; Xiao K; Persson JL; Chen L
BMC Med; 2020 Dec; 18(1):376. PubMed ID: 33256740
[TBL] [Abstract][Full Text] [Related]
38. PSA density improves prediction of prostate cancer.
Verma A; St Onge J; Dhillon K; Chorneyko A
Can J Urol; 2014 Jun; 21(3):7312-21. PubMed ID: 24978363
[TBL] [Abstract][Full Text] [Related]
39. [PSA and blood test diagnostics of prostate cancer].
Seikkula H; Pettersson K; Boström PJ
Duodecim; 2015; 131(17):1547-52. PubMed ID: 26548101
[TBL] [Abstract][Full Text] [Related]
40. Ultrasensitive electrochemical immunosensor for PSA biomarker detection in prostate cancer cells using gold nanoparticles/PAMAM dendrimer loaded with enzyme linked aptamer as integrated triple signal amplification strategy.
Kavosi B; Salimi A; Hallaj R; Moradi F
Biosens Bioelectron; 2015 Dec; 74():915-23. PubMed ID: 26257183
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]